Establishment of an efficient multiplex real-time PCR assay for human papillomavirus genotyping in cervical cytology specimens: Comparison with hybrid capture II

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Objective: To establish an efficient multiplex real-time PCR assay for 15 human papillomavirus (HPV) genotypes, we designed multiplexing parameters and compared our PCR system with the hybrid capture (HC) II test using cervical cytology samples. Methods: For preventing cross-reactive amplifications, variable HPV genes (E1, E2, E6, E7 and L1) were targeted. The melting temperatures of all primers and probes, and the size of the PCR product were optimized for the multiplex PCR. Our PCR system was compared with the HC II assays in the detection and genotyping of HPV infection using 173 cytology smears. Discordant cases between the two assays were verified by direct HPV DNA sequencing. Results: Of 173 women, 93 (53.8%) were HPV-positive by the HC II assay and/or the multiplex real-time PCR assay. The HPV genotypes were determined in 92 (98.9%) of 93 cases by the multiplex real-time PCR and/or DNA sequencing. The agreement rate between multiplex PCR and HC II methods was 91.9% (kappa=0.84). Although the sample size of this study needs to be increased to have epidemiological significance, multiple infections and HPV 16 were the predominant type. HPV 58, 52 and 18 accounted for 25% of HPV infections. HPV 52, 58 and 31 constituted 30% of CIN 2/3. Conclusion: The multiplex real-time PCR system shows a good and reliable clinical performance. This in house PCR assay is fast and cost-effective for HPV genotyping and the detection of HPV co-infection in the post-HPV vaccination era.

Original languageEnglish
Pages (from-to)261-268
Number of pages8
JournalCytopathology
Volume22
Issue number4
DOIs
Publication statusPublished - 2011 Aug 1

Fingerprint

Multiplex Polymerase Chain Reaction
Cell Biology
Real-Time Polymerase Chain Reaction
Papillomavirus Infections
Polymerase Chain Reaction
DNA Sequence Analysis
Human papillomavirus 31
Genotype
Human papillomavirus 18
Human papillomavirus 16
Computer Systems
Coinfection
Sample Size
Freezing
Vaccination
Costs and Cost Analysis
Temperature

Keywords

  • Cervical cytology
  • Genotyping
  • Human papillomavirus
  • Hybrid capture
  • Multiplex real-time PCR

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Histology

Cite this

@article{ea0edac0429b48c8a90cc2534dc2801e,
title = "Establishment of an efficient multiplex real-time PCR assay for human papillomavirus genotyping in cervical cytology specimens: Comparison with hybrid capture II",
abstract = "Objective: To establish an efficient multiplex real-time PCR assay for 15 human papillomavirus (HPV) genotypes, we designed multiplexing parameters and compared our PCR system with the hybrid capture (HC) II test using cervical cytology samples. Methods: For preventing cross-reactive amplifications, variable HPV genes (E1, E2, E6, E7 and L1) were targeted. The melting temperatures of all primers and probes, and the size of the PCR product were optimized for the multiplex PCR. Our PCR system was compared with the HC II assays in the detection and genotyping of HPV infection using 173 cytology smears. Discordant cases between the two assays were verified by direct HPV DNA sequencing. Results: Of 173 women, 93 (53.8{\%}) were HPV-positive by the HC II assay and/or the multiplex real-time PCR assay. The HPV genotypes were determined in 92 (98.9{\%}) of 93 cases by the multiplex real-time PCR and/or DNA sequencing. The agreement rate between multiplex PCR and HC II methods was 91.9{\%} (kappa=0.84). Although the sample size of this study needs to be increased to have epidemiological significance, multiple infections and HPV 16 were the predominant type. HPV 58, 52 and 18 accounted for 25{\%} of HPV infections. HPV 52, 58 and 31 constituted 30{\%} of CIN 2/3. Conclusion: The multiplex real-time PCR system shows a good and reliable clinical performance. This in house PCR assay is fast and cost-effective for HPV genotyping and the detection of HPV co-infection in the post-HPV vaccination era.",
keywords = "Cervical cytology, Genotyping, Human papillomavirus, Hybrid capture, Multiplex real-time PCR",
author = "Ju-Han Lee and Lee, {Nak Woo} and Hong, {S. W.} and Nam, {Y. S.} and Jung-Woo Choi and Kim, {Young Sik}",
year = "2011",
month = "8",
day = "1",
doi = "10.1111/j.1365-2303.2010.00787.x",
language = "English",
volume = "22",
pages = "261--268",
journal = "Cytopathology",
issn = "0956-5507",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Establishment of an efficient multiplex real-time PCR assay for human papillomavirus genotyping in cervical cytology specimens

T2 - Comparison with hybrid capture II

AU - Lee, Ju-Han

AU - Lee, Nak Woo

AU - Hong, S. W.

AU - Nam, Y. S.

AU - Choi, Jung-Woo

AU - Kim, Young Sik

PY - 2011/8/1

Y1 - 2011/8/1

N2 - Objective: To establish an efficient multiplex real-time PCR assay for 15 human papillomavirus (HPV) genotypes, we designed multiplexing parameters and compared our PCR system with the hybrid capture (HC) II test using cervical cytology samples. Methods: For preventing cross-reactive amplifications, variable HPV genes (E1, E2, E6, E7 and L1) were targeted. The melting temperatures of all primers and probes, and the size of the PCR product were optimized for the multiplex PCR. Our PCR system was compared with the HC II assays in the detection and genotyping of HPV infection using 173 cytology smears. Discordant cases between the two assays were verified by direct HPV DNA sequencing. Results: Of 173 women, 93 (53.8%) were HPV-positive by the HC II assay and/or the multiplex real-time PCR assay. The HPV genotypes were determined in 92 (98.9%) of 93 cases by the multiplex real-time PCR and/or DNA sequencing. The agreement rate between multiplex PCR and HC II methods was 91.9% (kappa=0.84). Although the sample size of this study needs to be increased to have epidemiological significance, multiple infections and HPV 16 were the predominant type. HPV 58, 52 and 18 accounted for 25% of HPV infections. HPV 52, 58 and 31 constituted 30% of CIN 2/3. Conclusion: The multiplex real-time PCR system shows a good and reliable clinical performance. This in house PCR assay is fast and cost-effective for HPV genotyping and the detection of HPV co-infection in the post-HPV vaccination era.

AB - Objective: To establish an efficient multiplex real-time PCR assay for 15 human papillomavirus (HPV) genotypes, we designed multiplexing parameters and compared our PCR system with the hybrid capture (HC) II test using cervical cytology samples. Methods: For preventing cross-reactive amplifications, variable HPV genes (E1, E2, E6, E7 and L1) were targeted. The melting temperatures of all primers and probes, and the size of the PCR product were optimized for the multiplex PCR. Our PCR system was compared with the HC II assays in the detection and genotyping of HPV infection using 173 cytology smears. Discordant cases between the two assays were verified by direct HPV DNA sequencing. Results: Of 173 women, 93 (53.8%) were HPV-positive by the HC II assay and/or the multiplex real-time PCR assay. The HPV genotypes were determined in 92 (98.9%) of 93 cases by the multiplex real-time PCR and/or DNA sequencing. The agreement rate between multiplex PCR and HC II methods was 91.9% (kappa=0.84). Although the sample size of this study needs to be increased to have epidemiological significance, multiple infections and HPV 16 were the predominant type. HPV 58, 52 and 18 accounted for 25% of HPV infections. HPV 52, 58 and 31 constituted 30% of CIN 2/3. Conclusion: The multiplex real-time PCR system shows a good and reliable clinical performance. This in house PCR assay is fast and cost-effective for HPV genotyping and the detection of HPV co-infection in the post-HPV vaccination era.

KW - Cervical cytology

KW - Genotyping

KW - Human papillomavirus

KW - Hybrid capture

KW - Multiplex real-time PCR

UR - http://www.scopus.com/inward/record.url?scp=79960481182&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960481182&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2303.2010.00787.x

DO - 10.1111/j.1365-2303.2010.00787.x

M3 - Article

C2 - 20636403

AN - SCOPUS:79960481182

VL - 22

SP - 261

EP - 268

JO - Cytopathology

JF - Cytopathology

SN - 0956-5507

IS - 4

ER -